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Introduction
Although some simple informative early clinical markers of 
disease course are available, individual prognosis in multi-
ple sclerosis (MS) remains unreliable and leads to difficul-
ties both in counseling and treatment of newly diagnosed 
patients. Decisions to initiate immunomodulatory treat-
ment often depend on recent inflammatory disease activity, 
whereas accurate personalised long-term prognosis, which 
might inform both the timing and type of treatment, remains 
elusive. This month’s journal club reviews three studies that 
examine the predictive value of early MRI features in deter-
mining selective long-term outcomes such as future physical 
and cognitive disability and transition to secondary progres-
sive disease phase. The use of brain imaging to visualise 
both cortical and chronically active ‘smouldering’ white 
matter lesions, may reduce the clinical-radiological para-
dox that has previously been described in MS. The studies 
outlined below explore some conventional and more novel 
MRI markers at baseline for their ability to predict subse-
quent disease progression and prognosis.
Early imaging predictors of long term 
outcomes in relapse‑onset multiple sclerosis
This study aimed to determine which early MRI features 
best predict future physical and cognitive disability, includ-
ing conversion to secondary progressive MS (SPMS) at 
15 years, in a cohort of relapse onset MS patients. Patients 
between the ages of 16 and 50 presenting to two special-
ist London hospitals with a clinically isolated syndrome 
(CIS) and no relevant previous neurological history were 
recruited (n = 178). Patients underwent MRI scans at base-
line, 1 year and 3 years to document intracerebral, spinal 
cord T2 lesions, gadolinium-enhancing lesions and total 
brain volume. They were then followed up at 15 years to 
assess disease course (either relapsing or SPMS), physical 
disability (expanded disability status scale (EDSS), timed 25 
foot walk and 9 hole peg test) and cognitive disability (paced 
auditory serial addition test and single digit modalities test).
In multivariate models, SPMS at 15 years was best pre-
dicted by a baseline scan demonstrating ≥ 2 gadolinium-
enhancing lesions or ≥ 1 spinal cord lesion (odds ratio 
3.16 and 4.71), or a 1-year scan demonstrating ≥ 1 new 
lesion (compared with baseline) in either the spinal cord or 
infratentorial compartment (odds ratio 5.72 and 7.02). The 
use of 3-year data added further weight to the predictions: 
in people with no new spinal or infratentorial lesions over 
the first 3 years after CIS the estimated risk of secondary 
progressive multiple sclerosis after 15 years was 0.9% (95% 
CI 0, 2.7%), compared with 53.1% (31.7, 74.6%) in patients 
with ≥ 1 new spinal and ≥ 1 new infratentorial lesions at 
3 years.
Early MRI lesions were also positively correlated with 
EDSS at 15 years, particularly gadolinium-enhancing and 
spinal cord lesions at baseline, and enhancing lesions at 
1 and 3 years. The authors conclude that early focal inflam-
matory activity and particularly spinal cord lesions pre-
dict long term outcomes in MS, including the transition to 
SPMS.
Comment This study measured baseline and early inter-
val change in brain and spinal cord MRI appearance in a 
large CIS cohort, and modeled the predictive value of lesion 
appearances and location for long-term physical and cogni-
tive outcomes. While many investigators are seeking novel 
biomarkers to use in MS, we ought not to forget that we 
do have some valuable tools already available to us in the 
clinic for predicting outcome. While many centres are try-
ing to limit the use of gadolinium for follow-up scans, here 
we see another reason why baseline scanning with contrast 
is valuable in MS. One of the uncertainties of this study is 
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the potential confounding effect disease modifying therapies 
(DMTs) may have had on outcomes. Since the cohort was 
recruited between 1994 and 2004, we might assume that the 
early imaging findings may have predated the widespread 
use of DMTs; later use of DMT may have influenced out-
comes. These data will add value by increasing the informa-
tion available to patients and clinicians at disease presenta-
tion, and should probably be factored into analyses of more 
novel prognostic biomarkers.
Brownlee WJ et al. (2019) Brain 142:2276–87
Longitudinal characterisation of cortical 
lesion development and evolution 
in multiple sclerosis
Post mortem histological examination of the brain demon-
strates that cortical demyelination is often more extensive 
than white matter demyelination in MS. However, cortical 
demyelination is not well visualized using conventional MRI 
techniques. This study used ultra high field (7T) MRI to 
explore the relationship between cortical lesion and white 
matter lesion accrual and to determine contribution of cor-
tical and white matter lesion load to cortical thickness and 
disability. Adults between the ages of 18 and 65 who had a 
diagnosis of clinically defined multiple sclerosis and were 
stable either on or off DMTs were recruited to between 2010 
and 2016. Patients underwent two interval 7T MRI scans to 
assess burden and distribution of cortical lesions and also 3T 
MRI to estimate cortical thickness. Disability progression 
was defined by a sustained increase in EDSS.
People with SPMS demonstrated higher cortical and 
white matter lesion counts and volumes compared to those 
with RRMS. Moreover, the rate of cortical lesion accumula-
tion was higher in people with RRMS who developed SPMS 
than in those who remained in RRMS (3.6 lesions/year vs. 
1.1 lesions/year respectively). Interestingly, the overall rate 
of accumulation of cortical lesions appeared both higher 
than, and independent of the accumulation of white matter 
lesions. Cortical lesion burden at baseline (but not white 
matter lesion burden) was found to correlate with baseline 
EDSS and to predict subsequent EDSS change. Cortical 
lesions were widely distributed across lobes but displayed a 
slight predominance for the sulci in RRMS.
Comment This longitudinal study used an ultra high-field 
MRI marker to predict subsequent disability outcomes in 
MS. Since 7T MRI is not available to most clinicians, this 
has limited immediate clinical utility, but serves as an impor-
tant reminder that conventional MRI is insensitive to some 
clinically relevant pathology in MS. Given the prevalence of 
grey matter demyelination in MS histopathology, improved 
MRI visualization, facilitating increased understanding of 
its clinical relevance, may prove to be important areas of 
future research.
Treaba CA et al. (2019) Radiology 291:740–9
Chronic white matter lesion activity predicts 
clinical progression in primary progressive 
multiple sclerosis
Histological examination of MS lesions reveals an important 
subgroup of lesions with ‘smouldering’ inflammatory activ-
ity, which is more notable in people with progressive MS, 
and may account for some of the gradual disability expe-
rienced by this group. Some T2 hyperintense lesions are 
observed to slowly expand over time, and some demonstrate 
greater T1 hypointensity, an imaging feature known to cor-
relate with greater axonal damage. This study used imag-
ing data acquired during the ORATARIO trial; the phase 3 
study of ocrelizumab versus placebo in people with primary 
progressive multiple sclerosis (PPMS), to explore the con-
tribution of MS lesion characteristics to clinical outcomes.
Key eligibility criteria for the ORATARIO trial were: 
age 18–55, diagnosis of PPMS, and EDSS 3–6.5. The pla-
cebo group demonstrated an increase in T2 lesion volume 
from baseline over 120 weeks, but the overall increase in 
T1 hypointense lesion volume was more than twice that 
of increase in T2 lesion volume. Slowly expanding lesions 
accounted for a small proportion of lesions overall, but a 
high amount of T1 lesion volume accumulation. This sug-
gests that smouldering activity within chronic lesions, rather 
than the appearance of new lesions, accounts for the major-
ity of the increase in T1 hypointense lesion volume.
Chronic lesion activity (the accumulation of T1 hypoin-
tensity within existing lesions) was the strongest predictor 
of disability outcomes, rather than brain volume loss or the 
rate of accumulation of new T1 or T2 lesions. Participants 
in the ocrelizumab arm had a lower rate of T1 and T2 lesion 
accumulation than those receiving placebo. Encouragingly, 
an ocrelizumab treatment effect was seen with regards to 
reduced accumulation of T1 hypointensity, both in new and 
existing lesions. The study authors concluded that increase 
in T1 lesion burden was largely due to smouldering disease 
activity within chronic lesions, and that this imaging finding 
was the best predictor of disease progression.
Comment This is a large, prospective imaging dataset 
from over 500 people with PPMS, where it was possible to 
characterise MS lesions according to T1 and T2 tissue con-
trast as well as whether ot not lesions were slowly expand-
ing. This revealed novel insights into the likely mechanism 
of accumulation of neuroaxonal pathology in progressive 
MS, but also brought encouragement that contemporary 
therapies may slow the accumulation of axonal pathol-
ogy. The study did not incorporate data on the anatomical 
3173Journal of Neurology (2019) 266:3171–3173 
1 3
location of lesions, which may have additional value in pre-
dicting outcome. For example, no spinal MRI data were col-
lected, which may be highly relevant in this patient cohort. 
The confirmation that smouldering lesions, which may have 
a different and unique pathology to acute lesions possibly 
with persistent inflammatory activation, may contribute sig-
nificantly to disease burden in this patient group is of consid-
erable interest and may prompt a future change in research 
and therapeutic direction.
Elliot C et al. (2019) Brain 142:2787–99
Summary All these studies provide valuable observations 
on underlying pathology, often not apparent in conventional 
imaging techniques and below the surface of what we might 
consider a ‘standard assessment’. In addition, together with 
clinical features, they increasingly raise the prospect of a 
more individualised approach to patient management and 
counselling and start to explain the reasons for the well-
described clinical-radiological paradox as well as the impor-
tance of grey matter pathology.
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